The program will explore the California Consumer Privacy Act (CCPA), the most comprehensive privacy law in the country, and the January 2020 updates that have significantly affected companies’ legal obligations. Attendees will learn the law’s basic framework, gain insight into compliance approaches from the both in-house and regulator perspectives, and review updates since the CCPA took effect.

David will co-lead a presentation on “The Outside Counsel Perspective,” alongside Jeffrey Tsai of DLA Piper.

The program is available to attend both online and in person.

For more information and to register, visit PLI’s website.

About David Rudolph

A partner in Lieff Cabraser’s San Francisco office, David Rudolph is a member of the firm’s Cybersecurity and Data Privacy and Antitrust and Intellectual Property practice groups. He has extensive experience litigating core technical issues in privacy cases, including in In re Anthem, Inc. Data Breach Litigation, MDL No. 2617 (N.D. Cal.), arising from a data breach that affected nearly 80 million of Anthem’s members, and in Campbell v. Facebook, Inc., No. 5:13-cv- 5996 (N.D. Cal.), in which Facebook users asserted that Facebook violated their privacy rights by scanning their private email messages.

David has represented end-payor classes in pharmaceutical antitrust litigation, including in the Cipro drug antitrust cases, the Restasis antitrust litigation, and the Generic Pharmaceuticals Price-Fixing cases. In 2017, David shared the “Outstanding Private Practice Antitrust Achievement” award from the American Antitrust Institute for his work on the Cipro case. He also represents plaintiffs in In re Domestic Airline Travel Antitrust Litigation (D.D.C.), a class action lawsuit alleging a conspiracy by United, American, Delta, and Southwest to artificially inflate domestic airline ticket prices by artificially limiting seating capacity.

David is also the author of Litigating Corporate Surveillance: Privacy, Autonomy, Power, and Democracy in the Courtroom (Routledge, 2025). In this book, he offers a critical corrective to prevailing views on the legality of corporate data exploitation practices, arguing that litigation—rather than legislation alone—is essential to enforcing privacy rights in democratic societies.

Hosted by the National Consumer Law Center (NCLC) and the National Association of Consumer Advocates (NACA), the annual event brings together leaders in the consumer law community to advance economic justice and strengthen protections for consumers nationwide.

Mark will speak on the panel “Taking Class Actions to Trial” on Sunday, November 16, alongside Len Bennett (Consumer Litigation Associates, PC), John Barrett (Bailey Glasser LLP), Shennan Kavanagh (NCLC), Shana Khader (Tycko & Zavareei LLP), and Jen Wagner (NCLC).

For more information and to view the full conference agenda, visit the event website.

About Mark Chalos

The Managing Partner of Lieff Cabraser’s Nashville office, Mark P. Chalos (twitter/X: @mpchalos) represents individuals who have suffered catastrophic personal injuries and families whose loved ones died due to the negligence or misconduct of others. Mark has tried cases before juries and judges across the country and serves in the leadership of numerous class actions and multidistrict litigations, including the national opioids litigation. He is Immediate Past-President of the Tennessee Trial Lawyers Association, an adjunct professor at Vanderbilt University Law School teaching The Practice of Aggregate Litigation, a frequent speaker at legal seminars nationwide on a variety of civil litigation topics, and is regularly cited by top-tier media outlets

Lieff Cabraser Heimann & Bernstein partner Rachel Geman presented an overview of Whistleblower/ False Claims Act litigation and what factors create an effective case for relators’ attorneys during the Southeast Complex Litigation Conference in Nashville in late October.

“You’re looking for a case that’s just the right mix, you might say,” Geman said. “Legitimate fraud against the government and the taxpayer, proper evidence, good timing.”

Specifically, she discussed the importance of documentary proof and knowledge of evidentiary sources within the parameters of what the relator can properly collect; of focusing on frauds that cry the most out for vindication – those that hurt people,  materially fleece the government, or turn important government objectives on their head; and the observation that a fraud that had been around for a very long time might suggest the need for more digging but a new fraud that has not yet cost the government much might unfortunately rapidly expand.

According to U.S. Government Accountability Office estimates, the federal government loses between $233 billion and $521 billion annually to fraud – based on most recent data from 2018 through 2022.

Geman and other presenters also discussed how most productively to work with the U.S. Department of Justice – which decides whether to intervene in private plaintiff Whistleblower/ FCA cases on behalf of the federal government.

The Southeast Complex Litigation Conference was presented by Lieff Cabraser and the Tennessee Bar Association.

About Rachel Geman

Rachel Geman is a partner in Lieff Cabraser’s New York office and the Chair of the firm’s False Claims/Qui Tam practice group. Her practice is dedicated to representing whistleblowers, writers and other rightsholders, employees, and consumers in complex class action and False Claims Act matters.  Rachel has served as the employee-side Chair of two ABA’s Labor & Employment Law Section Committees and the NELA/NY amicus committee. She is a CDRC-trained community mediator and an avocational writer.

The annual publication spotlights firms known for quality, specialized knowledge, and commitment to excellence, featuring only the top 4% of law firms nationwide.

In August, thirty-six of the firm’s attorneys were named to The Best Lawyers in America® 2026 edition, including seven associates recognized in Best Lawyers: Ones to Watch® in America 2026, highlighting the firm’s legal excellence across generations. In addition, three partners—Mark P. Chalos, Kelly M. Dermody, and Rachel Geman—received “Lawyer of the Year” honors in their respective practice areas, an accolade of particular significance, as only one lawyer in each practice area and designated metropolitan area is recognized each year.

Lieff Cabraser’s Tier 1 rankings for 2026 are:

National:

Mass Tort Litigation/Class Actions – Plaintiffs

Nashville:

Mass Tort Litigation / Class Actions – Plaintiffs
Personal Injury Litigation – Plaintiffs
Product Liability Litigation – Plaintiffs

New York:

Employment Law – Individuals
Mass Tort Litigation / Class Actions – Plaintiffs
Personal Injury Litigation – Plaintiffs
Product Liability Litigation – Plaintiffs

San Francisco:

Antitrust Law
Bet-the-Company Litigation
Employment Law – Individuals
Litigation – Antitrust
Litigation – Labor & Employment
Litigation – Securities
Mass Tort Litigation/Class Actions – Plaintiffs
Personal Injury Litigation – Plaintiffs
Product Liability Litigation – Plaintiffs

Congratulations to all!

In a November 3 letter to SEC Chairman Paul Atkins, the group criticized the September decision as “costly, unproven, and unwieldy,” warning that forced arbitration undermines transparency and accountability for investors. “Forced arbitration creates costly, uncertain, and inefficient proceedings that benefit no one—not participants, not plan sponsors, and ultimately not the companies themselves,” said Michael D. Scott, executive director of the National Coordinating Committee for Multiemployer Plans, in a statement to Bloomberg Law.

Read the full article on Bloomberg News (subscription required).

At the discussion included an overview of aggregate litigation types and how these legal mechanisms solve problems for both plaintiffs and defendants alike to create a “global peace.”

The most generally well-known of these options is Class Action litigation – in which a group of individuals comes together to address an injustice against a powerful defendant – generally a corporation or a government.

“Class actions are a common sense way to solve a shared problem between those harmed and those in power,” said Mark Chalos, managing partner of Lieff Cabraser Heimann & Bernstein’s Nashville office. “Class action litigation can change the way bad acting companies do business and get compensation for those harmed by wrongful conduct. For companies that believe they have acted properly, class actions can efficiently bring vindication in one fell swoop.”

Another legal mechanism for resolving complex civil cases is by way of multi-district litigation, often referred to as an MDL, which is a system of organizing multiple cases and types of cases against a common defendant (or defendants) in one federal court district for pre-trial proceedings – managed by one judge. Created by Congress in 1968, MDLs benefit plaintiffs, defendants, and American taxpayers by controlling costs, avoiding duplication, and preventing inconsistent pre-trial rulings.

The Southeast Complex Litigation Conference included leading voices from the plaintiffs’ bar, defense bar, government, and the bench, and was presented the Tennessee Bar Association.

About Mark P. Chalos

The Managing Partner of Lieff Cabraser’s Nashville office, Mark P. Chalos (twitter/X: @mpchalos) represents individuals who have suffered catastrophic personal injuries and families whose loved ones died due to the negligence or misconduct of others. Mark has tried cases before juries and judges across the country and serves in the leadership of numerous class actions and multidistrict litigations, including the national opioids litigation. He is Immediate Past-President of the Tennessee Trial Lawyers Association, an adjunct professor at Vanderbilt University Law School teaching The Practice of Aggregate Litigation, a frequent speaker at legal seminars nationwide on a variety of civil litigation topics, and is regularly cited by top-tier media outlets.

Our 2025 New York office Super Lawyers are Daniel Chiplock, Douglas Cuthbertson, Nicholas Diamand, Paulina do Amaral, Steven Fineman, Rachel Geman, Jason Lichtman, Annika K. Martin, Kelly McNabb, Michael Miarmi, Jonathan Selbin, Daniel Seltz, and David Stellings.

Lieff Cabraser’s New York Metro Rising Stars, all repeating their selection for 2025, are Patrick Andrews, Wesley Dozier, Wilson Dunlavey, Avery Halfon, Katherine “Kara” McBride, Jessica Moldovan, Gabriel Panek, and Sean Petterson.

Congratulations to all!

Class Period: February 23, 2022 – July 30, 2025

Lead Plaintiff Motion Deadline: December 15, 2025

Case information: https://lieffcabraser.com/securities/baxter/

Contact us: Email or text investorinfo@lchb.com or call 1-800-541-7358

Baxter, headquartered in Deerfield, Illinois, develops, manufactures, and markets medical products used in the healthcare industry. The Company recently launched the Novum LVP, a device that controls the delivery of intravenous (“IV”) fluids that carry medications, blood products, and nutrients to patients.

The action alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (a) Novum LVPs had been hampered by systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, which subject patients to serious risk of injury or death; (b) Baxter was notified of those Novum LVP malfunctions and related injuries and deaths; (c) Baxter’s attempts to remedy those defects were inadequate and  Novum LVP’s design flaws continued to cause serious harm to patients; and (d) as a result of the foregoing, there was a significant risk that Novum LVP customers would be asked to discontinue using existing Novum LVPs and that Baxter would pause new sales of the devices.

On April 7, 2025, Missouri news outlet KMOV reported significant safety issues with Novum LVP, specifically regarding the device’s inaccurate infusion rates, based on information from a whistleblower.  The KMOV report prompted the hospital system to take all its Novum LVPs out of service. Baxter nevertheless continued to promote the launch of Novum LVP and claimed it was a safe product.

On April 24, 2025, Baxter sent Novum LVP customers a warning letter about the device’s potential underinfusion risks and disclosed there had been only one serious injury linked to this issue.

On July 14, 2025, Baxter sent Novum LVP customers a second warning letter about the device’s risk of both underinfusion and overinfusion. The letter also disclosed that Baxter had received 79 serious injury reports and two reports of patient deaths tied to the device’s safety issues. Baxter, however, did not instruct hospitals to remove their Novum LVPs from service but rather directed them on correction steps while continuing to use the devices.

On July 31, 2025, Baxter announced that it was “voluntarily and temporarily paus[ing] shipments and planned installations of the Novum LVP,” and that the Company was “unable to currently commit to an exact timing for resuming shipment[s] and installation[s] for Novum LVPs.” Baxter’s Chief Operating Officer explained that the sales halt was in response to issues “we saw through our quality listening systems, customer feedback, and honestly our infusion data.” Following this news, Baxter’s stock price fell $6.29 per share, or 22.42%, from its closing price of $28.05 on July 30, 2025, to close at $21.76 on July 31, 2025, on significantly elevated trading volume.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with over 125 attorneys in offices in San Francisco, New York, Nashville, and Munich, Germany, is an internationally-recognized law firm committed to advancing the rights of investors and promoting corporate responsibility. Repeatedly recognized as a “Plaintiffs’ Powerhouse” by Law360, Lieff Cabraser has litigated some of the most important civil cases in the United States, and has assisted clients in recovering over $129 billion in verdicts and settlements. For over 50 years, Lieff Cabraser has remained committed to ensuring access to justice for all.

Source/Contact

Sharon Lee
Lieff Cabraser Heimann & Bernstein, LLP
6462604758
slee@lchb.com

Nimish discusses the options available to maintain anonymity, from filing under a pseudonym to using an incorporated entity, and explains the limits of each approach. He also examines how the outcome of a case, such as settlement, litigation, or dismissal, can affect a whistleblower’s ability to remain anonymous, and highlights federal whistleblower programs, including those administered by the SEC, IRS, and CFTC, where anonymity protections may be stronger. While no option guarantees complete anonymity, these strategies can be effective depending on the circumstances.

To read the full article, visit The Anti-Fraud Coalition’s website.

About Nimish R. Desai

A partner in Lieff Cabraser’s San Francisco office, Nimish R. Desai specializes in False Claims Act, class action, and environmental torts, and has helped secure over a billion dollar in settlements through his cases. He has been recognized as a Super Lawyer each year from 2013-2025 and has been repeatedly named to The Best Lawyers in America list in the field of Qui Tam Law.

Nimish currently serves as Chair of the Education Committee for The Anti-Fraud Coalition, the preeminent national whistleblower law organization, and regularly presents to national conferences on FCA topics. In his False Claims Act practice, he has represented whistleblower clients in the healthcare, military contracting, mortgage, and securities industries. In addition to managing numerous under seal matters, Nimish has litigated and won notable cases, including obtaining a $71 million settlement in a case alleging that a health plan and prominent hospitals defrauded the California and the United States of Medicaid funds by allegedly misrepresenting the plans’ medical loss ratio (MLR), and winning a $46 million false billing case settlement from one of California’s largest hospital systems.